Prostate Cancer Screening in Brazil: a single center experience in the public health system

Detalhes bibliográficos
Autor(a) principal: Oliveira,Renato Almeida Rosa de
Data de Publicação: 2021
Outros Autores: Guimarães,Gustavo Cardoso, Mourão,Thiago Camelo, Favaretto,Ricardo de Lima, Santana,Thiago Borges Marques, Lopes,Ademar, Zequi,Stenio de Cassio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300558
Resumo: ABSTRACT Purpose: Incidence and mortality of prostate cancer (PCa) are still increasing in developing countries. Limited access to the health system or more aggressive disease are potential reasons for this. Ethnic and social differences in developed countries seem to make inappropriate to extrapolate data from other centers. We aim to report the epidemiological profile of a PSA-screened population from a cancer center in Brazil. Materials and Methods: We retrospectively selected 9.692 men enrolled in a PCa prevention program, comprising total PSA level and digital rectal examination at the first appointment, associated with complementary tests when necessary. Men aged over 40 years-old were included after shared decision-making process. Prostate biopsy (TRUS) was performed when clinically suspected for PCa. After the diagnosis, patients underwent appropriate treatment. Results: TRUS was performed in 5.5% of men and PCa incidence was 2.6%. Overall ratio between number of patients who needed to be screened in order to diagnose one cancer was 38.9 patients, with 2.1 biopsies performed to diagnose a cancer. Positive predictive value (PPV) of TRUS biopsy in this strategy was 47.2%, varying from 38.5% (<50 years-old) to 60% (>80 years-old). We evidenced 70 patients (27.9%) classified as low risk tumors, 74 (29.5%) as intermediate risk, and 107 (42.6%) as high-risk disease. Conclusions: PSA-screening remains controversial in literature. In front of a huge miscegenated people and considering the big proportion of high-risk PCa, even in young men diagnosed with the disease, it is imperative to inform patients and health providers about these data particularities in Brazil.
id SBU-1_09dd54800fd0b2e2518d4638bc5c5a40
oai_identifier_str oai:scielo:S1677-55382021000300558
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Prostate Cancer Screening in Brazil: a single center experience in the public health systemProstate cancefamilial [Supplementary Concept]Mass ScreeningTherapeuticsABSTRACT Purpose: Incidence and mortality of prostate cancer (PCa) are still increasing in developing countries. Limited access to the health system or more aggressive disease are potential reasons for this. Ethnic and social differences in developed countries seem to make inappropriate to extrapolate data from other centers. We aim to report the epidemiological profile of a PSA-screened population from a cancer center in Brazil. Materials and Methods: We retrospectively selected 9.692 men enrolled in a PCa prevention program, comprising total PSA level and digital rectal examination at the first appointment, associated with complementary tests when necessary. Men aged over 40 years-old were included after shared decision-making process. Prostate biopsy (TRUS) was performed when clinically suspected for PCa. After the diagnosis, patients underwent appropriate treatment. Results: TRUS was performed in 5.5% of men and PCa incidence was 2.6%. Overall ratio between number of patients who needed to be screened in order to diagnose one cancer was 38.9 patients, with 2.1 biopsies performed to diagnose a cancer. Positive predictive value (PPV) of TRUS biopsy in this strategy was 47.2%, varying from 38.5% (<50 years-old) to 60% (>80 years-old). We evidenced 70 patients (27.9%) classified as low risk tumors, 74 (29.5%) as intermediate risk, and 107 (42.6%) as high-risk disease. Conclusions: PSA-screening remains controversial in literature. In front of a huge miscegenated people and considering the big proportion of high-risk PCa, even in young men diagnosed with the disease, it is imperative to inform patients and health providers about these data particularities in Brazil.Sociedade Brasileira de Urologia2021-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300558International braz j urol v.47 n.3 2021reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2020.0392info:eu-repo/semantics/openAccessOliveira,Renato Almeida Rosa deGuimarães,Gustavo CardosoMourão,Thiago CameloFavaretto,Ricardo de LimaSantana,Thiago Borges MarquesLopes,AdemarZequi,Stenio de Cassioeng2021-03-24T00:00:00Zoai:scielo:S1677-55382021000300558Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2021-03-24T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Prostate Cancer Screening in Brazil: a single center experience in the public health system
title Prostate Cancer Screening in Brazil: a single center experience in the public health system
spellingShingle Prostate Cancer Screening in Brazil: a single center experience in the public health system
Oliveira,Renato Almeida Rosa de
Prostate cance
familial [Supplementary Concept]
Mass Screening
Therapeutics
title_short Prostate Cancer Screening in Brazil: a single center experience in the public health system
title_full Prostate Cancer Screening in Brazil: a single center experience in the public health system
title_fullStr Prostate Cancer Screening in Brazil: a single center experience in the public health system
title_full_unstemmed Prostate Cancer Screening in Brazil: a single center experience in the public health system
title_sort Prostate Cancer Screening in Brazil: a single center experience in the public health system
author Oliveira,Renato Almeida Rosa de
author_facet Oliveira,Renato Almeida Rosa de
Guimarães,Gustavo Cardoso
Mourão,Thiago Camelo
Favaretto,Ricardo de Lima
Santana,Thiago Borges Marques
Lopes,Ademar
Zequi,Stenio de Cassio
author_role author
author2 Guimarães,Gustavo Cardoso
Mourão,Thiago Camelo
Favaretto,Ricardo de Lima
Santana,Thiago Borges Marques
Lopes,Ademar
Zequi,Stenio de Cassio
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira,Renato Almeida Rosa de
Guimarães,Gustavo Cardoso
Mourão,Thiago Camelo
Favaretto,Ricardo de Lima
Santana,Thiago Borges Marques
Lopes,Ademar
Zequi,Stenio de Cassio
dc.subject.por.fl_str_mv Prostate cance
familial [Supplementary Concept]
Mass Screening
Therapeutics
topic Prostate cance
familial [Supplementary Concept]
Mass Screening
Therapeutics
description ABSTRACT Purpose: Incidence and mortality of prostate cancer (PCa) are still increasing in developing countries. Limited access to the health system or more aggressive disease are potential reasons for this. Ethnic and social differences in developed countries seem to make inappropriate to extrapolate data from other centers. We aim to report the epidemiological profile of a PSA-screened population from a cancer center in Brazil. Materials and Methods: We retrospectively selected 9.692 men enrolled in a PCa prevention program, comprising total PSA level and digital rectal examination at the first appointment, associated with complementary tests when necessary. Men aged over 40 years-old were included after shared decision-making process. Prostate biopsy (TRUS) was performed when clinically suspected for PCa. After the diagnosis, patients underwent appropriate treatment. Results: TRUS was performed in 5.5% of men and PCa incidence was 2.6%. Overall ratio between number of patients who needed to be screened in order to diagnose one cancer was 38.9 patients, with 2.1 biopsies performed to diagnose a cancer. Positive predictive value (PPV) of TRUS biopsy in this strategy was 47.2%, varying from 38.5% (<50 years-old) to 60% (>80 years-old). We evidenced 70 patients (27.9%) classified as low risk tumors, 74 (29.5%) as intermediate risk, and 107 (42.6%) as high-risk disease. Conclusions: PSA-screening remains controversial in literature. In front of a huge miscegenated people and considering the big proportion of high-risk PCa, even in young men diagnosed with the disease, it is imperative to inform patients and health providers about these data particularities in Brazil.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300558
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000300558
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2020.0392
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.47 n.3 2021
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318078066950144